diazipine has been researched along with Osteoarthritis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banotai, C; Baum, H; Beidler, D; Bove, S; Braden, T; Cornicelli, J; Goodman, A; Gowan, R; Hicks, J; Lightle, S; Lu, XK; Miller, H; Ogden, A; Pandit, J; Plummer, MS; Roark, H; Sadagopan, N; Sanchez, B; Sarver, R; Shahripour, A; Shen, XQ; Skalitzky, DJ; Spessard, C; Stankovic, CJ; Welch, K; Whitehead, C | 2 |
2 other study(ies) available for diazipine and Osteoarthritis
| Article | Year |
|---|---|
Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Topics: Animals; Azirines; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclic Nucleotide Phosphodiesterases, Type 4; Dihydropyridines; Disease Models, Animal; Drug Evaluation, Preclinical; Osteoarthritis; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Protein Binding; Structure-Activity Relationship | 2013 |
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Topics: Analgesics; Animals; Azepines; Azirines; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Cyclic Nucleotide Phosphodiesterases, Type 2; Dihydropyridines; Disease Models, Animal; Drug Evaluation, Preclinical; Half-Life; Osteoarthritis; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Protein Binding; Pyrazoles; Rats; Structure-Activity Relationship | 2013 |